iTeos Therapeutics ITOS Stock
iTeos Therapeutics Price Chart
iTeos Therapeutics ITOS Financial and Trading Overview
| iTeos Therapeutics stock price | 10.15 USD |
| Previous Close | 13.99 USD |
| Open | 13.99 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 13.58 - 14.23 USD |
| 52 Week Range | 12.52 - 28.05 USD |
| Volume | 327.65K USD |
| Avg. Volume | 273.47K USD |
| Market Cap | 507.84M USD |
| Beta (5Y Monthly) | 1.31991 |
| PE Ratio (TTM) | 48.96552 |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.25 USD |
ITOS Valuation Measures
| Enterprise Value | -97177248 USD |
| Trailing P/E | 48.96552 |
| Forward P/E | -2.6741996 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.9767628 |
| Price/Book (mrq) | 0.7785088 |
| Enterprise Value/Revenue | -0.761 |
| Enterprise Value/EBITDA | 5.614 |
Trading Information
iTeos Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.31991 |
| 52-Week Change | -23.69% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 28.05 USD |
| 52 Week Low | 12.52 USD |
| 50-Day Moving Average | 14.43 USD |
| 200-Day Moving Average | 17.81 USD |
ITOS Share Statistics
| Avg. Volume (3 month) | 273.47K USD |
| Avg. Daily Volume (10-Days) | 336.98K USD |
| Shares Outstanding | 35.76M |
| Float | 24.52M |
| Short Ratio | 7.19 |
| % Held by Insiders | 0.26% |
| % Held by Institutions | 105.22% |
| Shares Short | 1.9M |
| Short % of Float | 9.43% |
| Short % of Shares Outstanding | 5.31% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 9.02% |
| Operating Margin (ttm) | -14.21% |
| Gross Margin | 100.00% |
| EBITDA Margin | -13.55% |
Management Effectiveness
| Return on Assets (ttm) | -1.43% |
| Return on Equity (ttm) | 1.80% |
Income Statement
| Revenue (ttm) | 127.7M USD |
| Revenue Per Share (ttm) | 3.59 USD |
| Quarterly Revenue Growth (yoy) | -91.70% |
| Gross Profit (ttm) | 267.63M USD |
| EBITDA | -17311000 USD |
| Net Income Avi to Common (ttm) | 11.52M USD |
| Diluted EPS (ttm) | 0.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 602.14M USD |
| Total Cash Per Share (mrq) | 16.84 USD |
| Total Debt (mrq) | 4.63M USD |
| Total Debt/Equity (mrq) | 0.71 USD |
| Current Ratio (mrq) | 23.348 |
| Book Value Per Share (mrq) | 18.24 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -113746000 USD |
| Levered Free Cash Flow (ttm) | -132718496 USD |
Profile of iTeos Therapeutics
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 321 Arsenal Street |
| ZIP | 02472 |
| Phone | 339 217 0161 |
| Website | https://www.iteostherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 125 |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Q&A For iTeos Therapeutics Stock
What is a current ITOS stock price?
iTeos Therapeutics ITOS stock price today per share is 10.15 USD.
How to purchase iTeos Therapeutics stock?
You can buy ITOS shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for iTeos Therapeutics?
The stock symbol or ticker of iTeos Therapeutics is ITOS.
Which industry does the iTeos Therapeutics company belong to?
The iTeos Therapeutics industry is Biotechnology.
How many shares does iTeos Therapeutics have in circulation?
The max supply of iTeos Therapeutics shares is 44.21M.
What is iTeos Therapeutics Price to Earnings Ratio (PE Ratio)?
iTeos Therapeutics PE Ratio is 0.00000000 now.
What was iTeos Therapeutics earnings per share over the trailing 12 months (TTM)?
iTeos Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the iTeos Therapeutics company belong to?
The iTeos Therapeutics sector is Healthcare.
iTeos Therapeutics ITOS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Global Market Composite NQGM | 2309.83 USD — |
+1.58
|
— — | 2282.44 USD — | 2312.75 USD — | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}